Cebon J S, Morstyn G
Melbourne Tumour Biology Branch, Royal Melbourne & Austin Hospitals, Victoria, Australia.
Cancer Surv. 1990;9(1):131-55.
GM-CSF has been used in clinical trials to assess its role in promoting the proliferation and differentiation of marrow cells and enhancing the functional activities of granulocytes and monocytes. These studies have indicated that GM-CSF may prove useful in the management of cancer patients by preventing or treating myelosuppression following cancer chemotherapy and in patients with myelodysplasia or aplastic anaemia. As well as determining the efficacy of GM-CSF as a therapeutic agent, these studies are also providing insights into the possible roles of GM-CSF in vivo. Pharmacokinetic studies of GM-CSF in patients with advanced cancer and myelodysplasia suggest that the ratio of efficacy to toxicity of GM-CSF can be modified by changing either the dose or the method of administration.
粒细胞-巨噬细胞集落刺激因子（GM-CSF）已用于临床试验，以评估其在促进骨髓细胞增殖和分化以及增强粒细胞和单核细胞功能活性方面的作用。这些研究表明，GM-CSF在癌症化疗后预防或治疗骨髓抑制以及骨髓增生异常或再生障碍性贫血患者中可能证明是有用的。除了确定GM-CSF作为治疗剂的疗效外，这些研究还为GM-CSF在体内的可能作用提供了见解。对晚期癌症和骨髓增生异常患者的GM-CSF药代动力学研究表明，GM-CSF的疗效与毒性之比可以通过改变剂量或给药方法来改变。
